NDA 218139 · Novitium Pharma
Tezruly
Terazosin Hydrochloride · Oral
DiscontinuedLast checked: Nov 20, 2026Latest source record: Jul 29, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2024
Jul 29, 2024
Approved uses
1
Original approval plus efficacy supplements
Registered trials
33
7 Phase 3, 4 recruiting
FAERS reports
7,627
5,231 serious, 857 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Apr 18, 2025.
TEZRULY TM (terazosin) is an alpha-1 adrenoceptor antagonist indicated for: The treatment of signs and symptoms of benign prostatic hyperplasia (BPH) (1.1) The treatment of hypertension alone or with other antihypertensive agents, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarction. (1.2) 1.1 Benign Prostatic Hyperplasia TEZRULY is indicated for the treatment of the signs and symptoms of benign prostatic hyperplasia (BPH) in adult males [see Clinical Studies (14.1)] . 1.2 Hypertension TEZRULY is indicated for the treatment of hypertension, to lower blood pressure in adults [see Clinical Studies (14.2)] . Lowering blood pressure reduces the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure...
Mechanism: Benign Prostatic Hyperplasia The symptoms associated with benign prostatic hyperplasia (BPH) are related to bladder outlet obstruction, which is comprised of two underlying components: static and dynamic. The static component is related to an increase in prostate size caused, in part by a proliferation of smooth muscle cells in the prostatic stroma. However, the severity of BPH symptoms and the degree of urethral obstruction do not correlate well with the size of the prostate. The dynamic component is a function of an increase in smooth muscle tone in the prostate and bladder neck. The degree...
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
1 products under this application
- TEZRULY · TERAZOSIN HYDROCHLORIDE EQ 1MG BASE/ML · SOLUTION, ORAL · Discontinued
Clinical trials
Interventional ClinicalTrials.gov studies with "Terazosin" as an intervention, any sponsor and status, largest first.
- Action to Control Cardiovascular Risk in Diabetes (ACCORD)Pivotal-lookingCompleted
National Heart, Lung, and Blood Institute (NHLBI)NIH
NCT00000620 · 10,251 participants · Start Sep 1999 · Primary completion Jun 2009
Drug: Anti-hyperglycemic Agents; Anti-hypertensive Agents and 1 more · For: Atherosclerosis; Cardiovascular Diseases; Hypercholesterolemia and 4 more
Sites: Minneapolis, Minnesota; New York, New York; Winston-Salem, North Carolina · 7 sites in all
- FLOMAX® Versus HYTRIN® in Patients With the Signs and Symptoms of Benign Prostatic HyperplasiaPivotal-lookingCompleted
Boehringer IngelheimBoehringer Ingelheim
NCT02244255 · 1,993 participants · Start Aug 1998 · Primary completion Jun 2000
Drug: FLOMAX® capsules; Ascending doses of HYTRIN® capsules · For: Prostatic Hyperplasia
- Edmond J. Safra Accelerating Clinical Trials in Parkinson's Disease: A Multiarm Multi-stage Platform TrialPivotal-lookingRecruiting
University College, LondonAcademic, hospital or other
NCT07207057 · 1,200 participants (planned) · Start Sep 12, 2025 · Primary completion May 2031
Drug: Placebo; Telmisartan and 1 more · For: Parkinsons Disease (PD)
Sites: London, United Kingdom; Newcastle, United Kingdom
- Effect of Amlodipine Monotherapy or Combined With Terazosin on Lower Urinary Tract Symptoms and HypertensionPivotal-lookingCompleted
Anhui Medical UniversityAcademic, hospital or other
NCT00693199 · 360 participants · Start Jul 2006 · Primary completion Oct 2006
Drug: amlodipine; terazosin and 1 more · For: Lower Urinary Tract Symptoms; Hypertension
Sites: Hefei, China
- Atrial Substrate Modification With Aggressive Blood Pressure Lowering to Prevent AFPivotal-lookingCompleted
Nova Scotia Health AuthorityAcademic, hospital or other
NCT00438113 · 184 participants · Start Dec 2009 · Primary completion Sep 2016
Drug: Aggressive Blood Pressure control · For: Atrial Fibrillation
Sites: Halifax, Canada
- Safety and Efficacy of Low Dosage of Terazosin in Subjects Undergoing Carotid Artery StentingPivotal-lookingStatus unknown
Capital Medical UniversityAcademic, hospital or other
NCT03195673 · 160 participants (planned) · Start Mar 2, 2018 · Primary completion Nov 15, 2019
Drug: Terazosin · For: Carotid Artery Stenosis
Sites: Beijing, China · 2 sites in all
- Comparison of Alpha Blockers (Terazosin and Tamsulosin) in Reducing Ureteral Stent Related SymptomsPivotal-lookingRecruiting
Penang Hospital, MalaysiaGovernment (non-federal)
NCT06966804 · 150 participants (planned) · Start Jun 1, 2025 · Primary completion May 31, 2027
Drug: Terazosin; Tamsulosin · For: Stent Related Symptoms
Sites: Alor Star, Malaysia; George Town, Malaysia
- Randomized Trial Comparing Terazosin 5 mg Daily and Doxazosin GITS 4 mg Daily for Trial Without Catheter in Acute Urinary Retention With Long Term Follow upPivotal-lookingTerminated
Hospital Authority, Hong KongGovernment (non-federal)
NCT00563485 · 120 participants (planned) · Start Oct 2005
Drug: Doxazosin GITS (Cardura XL); Terazosin (Hytrin) · For: Prostatic Hyperplasia; Urinary Retention
Sites: Hong Kong, China
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- drug ineffective489
- fatigue478
- diarrhoea402
- dizziness397
- dyspnoea395
- asthenia367
- acute kidney injury357
- death344
- chronic kidney disease320
- off label use315
- renal failure303
- nausea296
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 9 |
| 2005 | 235 |
| 2006 | 52 |
| 2007 | 11 |
| 2008 | 15 |
| 2009 | 45 |
| 2010 | 35 |
| 2011 | 138 |
| 2012 | 190 |
| 2013 | 417 |
| 2014 | 517 |
| 2015 | 754 |
| 2016 | 751 |
| 2017 | 703 |
| 2018 | 686 |
| 2019 | 674 |
| 2020 | 549 |
| 2021 | 484 |
| 2022 | 353 |
| 2023 | 323 |
| 2024 | 251 |
| 2025 | 259 |
| 2026 | 175 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Terazosin for benign prostatic hyperplasia.
Wilt TJ, Howe RW, Rutks IR, et al. · Cochrane Database Syst Rev 2002 · Meta-Analysis, Systematic Review
- Tamsulosin for benign prostatic hyperplasia.
Wilt TJ, Mac Donald R, Rutks I · Cochrane Database Syst Rev 2003 · Meta-Analysis, Systematic Review
- Clonidine for post-traumatic stress disorder: a systematic review of the current evidence.
Marchi M, Grenzi P, Boks MP · Eur J Psychotraumatol 2024 · Systematic Review, Research Support, Non-U.S. Gov't
- WITHDRAWN: Terazosin for benign prostatic hyperplasia.
Wilt TJ, Howe RW, Rutks I, et al. · Cochrane Database Syst Rev 2011 · Systematic Review
- Finasteride for benign prostatic hyperplasia.
Tacklind J, Fink HA, Macdonald R, et al. · Cochrane Database Syst Rev 2010 · Meta-Analysis, Systematic Review
- alpha1-adrenoceptor selectivity: the North American experience.
Wyllie MG · Eur Urol 1999 · Clinical Trial, Randomized Controlled Trial
Sponsor: Novitium Pharma
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.